Dr Richard Treagus joins Neuren Board as Executive Chairman

SYDNEY, Australia, 31 January 2013: Neuren Pharmaceuticals Limited (ASX:NEU) is pleased to announce that Dr Richard Treagus has joined its Board. Dr Treagus will also become the Board’s Executive Chairman. He will be engaged in an executive capacity to review Neuren’s business, financial and commercial strategy. He will work with Larry Glass, the Company’s CEO and Managing Director, in executing the Company’s business plan to realize Neuren’s value for shareholders.

An experienced and highly regarded pharmaceutical leader, Richard has an extensive global network and a strong track record of being able to deliver exceptional outcomes and shareholder returns in a complex business environment. Combining his medical training with a business qualification, Richard has over 20 years’ strategic and operational experience in all aspects of the international pharmaceutical industry.

He has held a variety of senior executive roles with pharmaceutical organisations in South Africa and Australia, and over the years has successfully built numerous business partnerships across the US, Europe and Asia. Richard’s most recent role was as Chief Executive of ASX-listed company Acrux which, under his leadership, concluded the largest product licensing deal in the history of the Australian biotech industry, a transaction with Eli Lilly worth US$335m plus royalties.

The Board expects that Richard will be able to use his experience, his extensive business network and his knowledge of the Australian capital markets in particular, to help realize Neuren’s full potential and the market’s appreciation of it.

Dr Robin Congreve, who has led Neuren since its listing on the ASX in 2004 will remain on the Board. In welcoming Richard to the Board, he said: “I and my fellow Board members look forward to working with Richard and Larry to complete the clinical trials now under way and planned, to advance the development of some exciting new possibilities, especially in the autism spectrum disorders, and to realize Neuren’s true commercial value.

Dr Treagus added: “I am delighted to be joining Neuren at this time. The recent progress that the Company has made in identifying a number of highly promising product candidates is tremendously exciting. I am very much looking forward to working with the Board, Larry and the entire Neuren team to ensure that we have the optimum strategy, resources and execution necessary to advance product development and deliver full value for our shareholders”.

About Neuren
Neuren Pharmaceuticals is a biopharmaceutical company developing new therapies for brain injury, neurodevelopmental and neurodegenerative disorders and cancer. Neuren presently has two clinical-
stage molecules, NNZ-2566 and Motiva®, in Phase II clinical trials largely funded by the US Army and the National Health and Medical Research Council, respectively. Through its subsidiary, Perseis Therapeutics Limited, Neuren is developing monoclonal antibodies against Trefoil Factors 1 and 3, proteins produced by cancer cells that are associated with cancer spread and reduced patient survival.

For more information, please contact:

Larry Glass, Neuren CEO
lglass@neurenpharma.com
Tel: +1 301 941 1830

Dr Richard Treagus
Tel: +61 417 520 509